Growth differentiation factor (GDF)-15 blocks norepinephrineinduced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation

Journal of Biological Chemistry

Volumn 289, Issue 14, 2014, Pages 10084-10094

  Xu, Xin Ye ^a   Nie, Ying ^a   Wang, Fang Fang ^a   Bai, Yan ^a   Lv, Zhi Zhen ^a   Zhang, You Yi ^a   Li, Zi Jian ^a   Gao, Wei ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL MEMBRANES; NOREPINEPHRINE;

CARDIO-VASCULAR DISEASE; EPIDERMAL GROWTH FACTOR RECEPTORS; GROWTH DIFFERENTIATION; HYPERTENSIVE PATIENTS; LEFT VENTRICULAR MASS; LEUCINE INCORPORATION; MYOCARDIAL HYPERTROPHY; RECEPTOR TRANSACTIVATION;

BODY FLUIDS;

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH DIFFERENTIATION FACTOR 15; MITOGEN ACTIVATED PROTEIN KINASE 1; NORADRENALIN; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION;

CARDIAC HYPERTROPHY; CELL SIGNALING; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); GROWTH DIFFERENTIATION FACTOR 15; GROWTH FACTORS; HYPERTENSION; NOREPINEPHRINE; TRANSACTIVATION;

ADRENERGIC ALPHA-AGONISTS; CARDIOMEGALY; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; MYOCARDIUM; NOREPINEPHRINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84898063190     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.516278     Document Type: Article

References (35)

1. Lee, S. J. (1990) Identification of a novel member (GDF-1) of the transforming growth factor-/3 superfamily. Mol. Endocrinol. 4, 1034-1040
2. Bootcov, M. R., Bauskin, A. R., Valenzuela, S. M., Moore, A. G., Bansal, M., He, X. Y., Zhang, H. P., Donnellan, M., Mahler, S., Pryor, K., Walsh, B. J., Nicholson, R. C, Fairlie, W. D., Por, S. B., Robbins, J. M., and Breit, S. N. (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-/3 superfamily. Proc. Natl. Acad. Sci. U.S.A. 94, 11514-11519
3. Xu, X., Li, Z., and Gao, W. (2011) Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers 16, 466-475
4. Wollert, K. C., Kempf, T., Peter, T., Olofsson, S., James, S., Johnston, N, Lindahl, B., Horn-Wichmann, R., Brabant, G., Simoons, M. L., Armstrong, P. W., Califf, R. M., Drexler, H., and Wallentin, L. (2007) Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 115, 962-971
5. Kempf, T., von Haehling, S., Peter, T., Allhoff, T., Cicoira, M., Doehner, W., Ponikowski, P., Filippatos, G. S., Rozentryt, P., Drexler, H., Anker, S.D., and Wollert, K. C. (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1054-1060
6. Kempf, T., Bjorklund, E., Olofsson, S., Lindahl, B., Allhoff, T., Peter, T., Tongers, J., Wollert, K. C., and Wallentin, L. (2007) Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur. Heart J. 28, 2858-2865
7. Khan, S. Q., Ng, K., Dhillon, O., Kelly, D., Quinn, P., Squire, I. B., Davies, J. E., and Ng, L. L. (2009) Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 30, 1057-1065
8. Anand, I. S., Kempf, T., Rector, T. S., Tapken, H., Allhoff, T., Jantzen, F., Kuskowski, M., Cohn, J. N., Drexler, H., and Wollert, K. C. (2010) Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122, 1387-1395
9. Eggers, K. M., Kempf, T., Lagerqvist, B., Lindahl, B., Olofsson, S., Jantzen, F., Peter, T., Allhoff, T., Siegbahn, A., Venge, P., Wollert, K. C., and Wallentin, L. (2010) Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-eleva-tion acute coronary syndrome. Circ Cardiovasc Genet. 3, 88-96
10. Kempf, T., Horn-Wichmann, R., Brabant, G., Peter, T., Allhoff, T., Klein, G., Drexler, H., Johnston, N, Wallentin, L., and Wollert, K. C. (2007) Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin. Chem. 53, 284-291
11. Eggers, K. M., Kempf, T., Lind, L., Sundstrom, J., Wallentin, L., Wollert, K. C., and Siegbahn, A. (2012) Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scand. J. Clin. Lab. Invest. 72, 45-51
12. Wang, F., Guo, Y., Yu, H., Zheng, L., Mi, L., and Gao, W. (2010) Growth differentiation factor 15 in different stages of heart failure: potential screening implications. Biomarkers 15, 671-676
13. Dominguez-Rodriguez, A., Abreu-Gonzalez, P., and Avanzas, P. (2011) Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction. Am. J. Cardiol. 108, 955-958
14. Lind, L., Wallentin, L., Kempf, T., Tapken, H., Quint, A., Lindahl, B., Olofsson, S., Venge, P., Larsson, A., Hulthe, J., Elmgren, A., and Wollert, K. C. (2009) Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur. Heart J. 30, 2346-2353
15. Wang, X., Yang, X., Sun, K., Chen, J., Song, X., Wang, H., Liu, Z., Wang, C, Zhang, C, and Hui, R. (2010) The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension. Clin. Sci. 118, 137-145
16. Bjørnstad, J. L., Neverdal, N. O., Vengen, O. A., Knudsen, C. W., Husebye, T., Pepper, J., Lie, M., Christensen, G., and Tønnessen, T. (2008) Alterations in circulating activin, A., GDF-15, TGF-/33 and MMP-2,-3, and-9 during one year of left ventricular reverse remodeling in patients operated for severe aortic stenosis. Eur. J. Heart Fail. 10, 1201-1207
17. Montoro-García, S., Hernandez-Romero, D., Jover, E., García-Honrubia, A., Vilchez, J. A., Casas, T., Martínez, P., Climent, V., Caballero, L., Valdes, M., and Marín, F. (2012) Growth differentiation factor-15, a novel bio-marker related with disease severity in patients with hypertrophic cardiomyopathy. Eur. J. Intern Med. 23, 169-174
18. Xu, J., Kimball, T. R., Lorenz, J. N, Brown, D. A., Bauskin, A. R., Klevitsky, R., Hewett, T. E., Breit, S. N, and Molkentin, J. D. (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ. Res. 98, 342-350
19. Heger, J., Schiegnitz, E., vonWaldthausen, D., Anwar, M. M., Piper, H. M., and Euler, G. (2010) Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. J. Cell. Physiol. 224, 120-126
20. Parati, G., and Esler, M. (2012) The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur. Heart J. 33, 1058-1066
21. Cacciapuoti, F. (2011) Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives. J.Am. Soc.Hypertens. 5, 449-455
22. Chen, Z., Hague, C, Hall, R. A., and Minneman, K. P. (2006) Syntrophins regulate a1D-adrenergic receptors through a PDZ domain-mediated interaction. J. Biol. Chem. 281, 12414-12420
23. 2+ homeostasis and contraction but dispensable for/3-adrenergic stimulation of adult cardiomyocytes. J. Muscle Res. CellMotil. 32, 243-248
24. Schillaci, G., De Vuono, S., and Pucci, G. (2011) An endogenous brake on the sympathetic nervous system: the emerging role of catestatin in hypertension. J. Cardiovasc. Med. (Hagerstown) 12, 609-612
25. Kempf, T., Eden, M., Strelau, J., Naguib, M., Willenbockel, C, Tongers, J., Heineke, J., Kotlarz, D., Xu, J., Molkentin, J. D., Niessen, H. W., Drexler, H, and Wollert, K. C. (2006) The transforming growth factor-/3 superfamily member growth-differentiation factor-15 protects the heart from ische-mia/reperfusion injury. Circ. Res. 98, 351-360
26. Kempf, T., Zarbock, A., Widera, C, Butz, S., Stadtmann, A., Rossaint, J., Bolomini-Vittori, M., Korf-Klingebiel, M., Napp, L. C, Hansen, B., Kan-wischer, A., Bavendiek, U., Beutel, G., Hapke, M., Sauer, M. G., Laudanna, C., Hogg, N, Vestweber, D., and Wollert, K. C. (2011) GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 17, 581-588
27. q mediated hypertrophy. J. Mol. Cell. Cardiol. 40, 597-604
28. Li, Y., Zhang, H, Liao, W., Song, Y., Ma, X., Chen, C, Lu, Z., Li, Z., and Zhang, Y. (2011) Transactivated EGFR mediates a-AR-induced STAT3 activation and cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 301, H1941-H1951
29. Noma, T., Lemaire, A., Naga Prasad, S. V., Barki-Harrington, L., Tilley, D. G., Chen, J., Le Corvoisier, P., Violin, J. D., Wei, H., Lefkowitz, R. J., and Rockman, H. A. (2007)/3-arrestin1-mediated/31-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117, 2445-2458
30. McMurray, J. J., Adamopoulos, S., Anker, S. D., Auricchio, A., Bohm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C, Gomez-Sanchez, M. A., Jaarsma, T., Køber, L., Lip, G. Y., Maggioni, A. P., Parkhomenko, A., Pieske, B. M., Popescu, B. A., Rønnevik, P. K., Rutten, F. H., Schwitter, J., Seferovic, P., Stepinska, J., Trindade, P. T., Voors, A. A., Zannad, F., Zeiher, A., and ESC Committee for Practice Guidelines (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur. Heart J. 33, 1787-1847
31. Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Ger-mano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Narkie-wicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R. E., Struijker Boudier, H. A., Zanchetti, A., Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C, Hellemans, I., Kris-tensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widim-sky, P., Zamorano, J. L., Kjeldsen, S. E., Erdine, S., Narkiewicz, K., Kiowski, W, Agabiti-Rosei, E., Ambrosioni, E., Cifkova, R., Dominiczak, A., Fagard, R., Heagerty, A. M., Laurent, S., Lindholm, L. H., Mancia, G., Manolis, A., Nilsson, P. M., Redon, J., Schmieder, R. E., Struijker-Boudier, H. A., Viigi-maa, M., Filippatos, G., Adamopoulos, S., Agabiti-Rosei, E., Ambrosioni, E., Bertomeu, V., Clement, D., Erdine, S., Farsang, C, Gaita, D., Kiowski, W., Lip, G., Mallion, J. M., Manolis, A. J., Nilsson, P. M., O'Brien, E., Ponikowski, P., Redon, J., Ruschitzka, F., Tamargo, J., van Zwieten, P., Viigimaa, M., Waeber, B., Williams, B., Zamorano, J. L., The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH), and of the European Society of Cardiology (ESC) (2007) 2007 Guidelines for the management of arterial hypertension. Eur. Heart J. 28, 1462-1536
32. Muslin, A. J. (2008) MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin. Sci. 115, 203-218
33. Muslin, A. J., and DeBosch, B. (2006) Role of Akt in cardiac growth and metabolism. Novartis Found. Symp. 274, 118-131
34. Ruskoaho, H, and Leppaluoto, J. (1988) Immunoreactive atrial natriuretic peptide in ventricles, atria, hypothalamus, and plasma of genetically hypertensive rats. Circ. Res. 62, 384-394
35. Xue, H, Fu, Z., Chen, Y., Xing, Y., Liu, J., Zhu, H., and Zhou, X. (2012) The association of growth differentiation factor-15 with left ventricular hypertrophy in hypertensive patients. PLoS One 7, e46534